Clinical trials: Bullous Dermatoses
Steven-Johnson Syndrome, Toxic Epidermal Necrolysis
Severe Cutaneous Adverse Reactions in Thailand
The multicenter registry of patients with severe cutaneous adverse reactions among tertiary medical institutes in Thailand to study clinical characteristics, etiologies, therapeutic outcomes, quality of life, and the values of in…
- Conditions
- Steven-Johnson Syndrome, Toxic Epidermal Necrolysis, Drug Reaction With Eosinophilia and Systemic Symptoms, Acute Generalized Exanthematous Pustulosis
- Trial name
- ThaiSCAR (NCT02574988)
- Where
- Thailand
- Volunteers
- 200 people
- Sponsor
- Chulalongkorn University
Pemphigoid, Bullous
Cytokines in Blister Fluids of Bullous Pemphigoid (BP)
This study investigates the differences of Eosinophil Cationic Protein, Tumor Necrosis Factor-alpha and Anti-BP180-NC16A IgG levels of blister fluids in Bullous Pemphigoid patients which appeared before and under treatment…
- Trial name
- BP (NCT03856840)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 21 people
- Sponsor
- Mahmut Can Koska
Bullous Pemphigoid, Immunotherapy
Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy
Immune checkpoint inhibitors (monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD- L1)) have revolutionized the treatment…
- Conditions
- Bullous Pemphigoid, Immunotherapy, Programmed Cell Death Ligand 1
- Trial name
- NCT04641884
- Testing
- Not concerned
- Where
- France
- Volunteers
- 85 people
- Sponsor
- Nantes University Hospital
Bullous Pemphigoid
Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid
Clinical observation frequently shows a paradoxical effect of topical corticosteroids in charge of a sudden melting of edema in the first days of treatment, which could be due to mobilization of extracellular.
- Trial name
- RECOPB (NCT02360202)
- Testing
- Impedance analysis, Clobetasol Propionate cream treatment
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Rouen
Bullous Pemphigoid
Rituximab in the Treatment of Patients With Bullous Pemphigoid
This study will determine the safety of treatment of bullous pemphigoid in patients resistant to therapy with systemic corticosteroids, with rituximab plus systemic corticosteroids.
- Trial name
- NCT00286325
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Duke University
Bullous Pemphigoid
Efficacy and Safety of add-on Dapsone Versus add-on Methotrexate in Patients With Bullous Pemphigoid
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disorder most commonly affecting the older population between 60-80 years old.
- Trial name
- NCT05984381
- Testing
- Prednisolone, Dapsone, Methotrexate
- Where
- India
- Volunteers
- 62 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Bullous Pemphigoid
Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients
Bullous pemphigoid affects mainly elderly patients. It is often associated with neurologic disorders, which represent a major risk factor of the disease
- Trial name
- NCT03320798
- Testing
- Data record
- Where
- France
- Volunteers
- 178 people
- Sponsor
- CHU de Reims
Autoimmune Bullous Dermatosis, Dysimmune Dermatological Diseases
Clinico-biological Collection of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases
The aim of this project is to start a biological and clinical collection of patients presenting autoimmune, dysimmune or auto-inflammatory dermatological diseases.
- Conditions
- Autoimmune Bullous Dermatosis, Dysimmune Dermatological Diseases, Auto-inflammatory Dermatological Diseases, Skin Diseases
- Trial name
- TekAPo (NCT06387654)
- Testing
- Blood sampling, Remainders of samples taken as part of the treatment
- Where
- France
- Volunteers
- 800 people
- Sponsor
- University Hospital, Toulouse
Atopic Dermatitis, Psoriasis
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
Chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. They affect the skin but also other organs (joints, lungs, muscles, etc.). Their prognosis and response to treatments is extremely variable.
- Conditions
- Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Lichen Planus
- Trial name
- ImmuneSkinBank (NCT06599411)
- Testing
- Sampling
- Where
- France
- Volunteers
- 830 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pemphigus Vulgaris, Pemphigus Foliaceus
Autoimmune Blistering Diseases Study
Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches.
- Conditions
- Pemphigus Vulgaris, Pemphigus Foliaceus, Bullous Pemphigoid
- Trial name
- AIBD (NCT02753777)
- Testing
- Questionnaires
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of Pennsylvania
Allergic Cutaneous Vasculitis, Urticaria
Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome
This Study is to evaluate the utility of prospective HLA-B*1301 screening on the incidence of dapsone hypersensitivity syndrome (DHS) in 3130 previously Dapsone(DDS)-naive patients.
- Conditions
- Allergic Cutaneous Vasculitis, Urticaria, Psoriasis, Acne
- Trial name
- NCT02550080
- Testing
- Dapsone, HLA-B*1301
- Where
- China
- Volunteers
- 3,130 people
- Sponsor
- Shandong Provincial Institute of Dermatology and Venereology
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP)
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose…
- Conditions
- Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
- Trial name
- NCT06371417
- Testing
- RAY121
- Where
- 77 sites in United States, Australia and 18 more
- Volunteers
- 144 people
- Sponsor
- Chugai Pharmaceutical
Rare Diseases, Toxic Epidermal Necrolyses
Severe Bullous Drug Eruption and Filgrastim
Toxic epidermal necrolysis (TEN) including Stevens Johnson (SJS) and Lyell syndromes represent the most severe drug eruptions. It is an allergic disorder caused by cytotoxic T lymphocytes, specific of drugs, responsible for the…
- Trial name
- GNET (NCT04651439)
- Testing
- Filgrastim
- Where
- 3 sites in France
- Volunteers
- 42 people
- Sponsor
- Hospices Civils de Lyon
Bullous Pemphigoid
Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid
To evaluate the efficacy of rituximab combined with omalizumab in achieving sustained complete remission, evaluated by Bullous Pemphigoid Disease Area Index (BPDAI) in patients with bullous pemphigoid (BP) at Week 24 in patients…
- Trial name
- NCT04128176
- Testing
- Rituximab combined with Omalizumab
- Where
- United States
- Sponsor
- University of California, Davis
Bullous Pemphigoid
Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid
Bullous pemphigoid (BP) is the most common blistering auto-immune disease of skin with an incidence estimated to 400 new cases per year.
- Trial name
- ARABUL (NCT00802243)
- Testing
- leflunomide
- Where
- 3 sites in France
- Volunteers
- 54 people
- Sponsor
- University Hospital, Limoges
Bullous Pemphigoid (BP), Cold Agglutinin Disease (CAD)
Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders
Prospective, double-blind, randomized, placebo-controlled First-In-Human study with four sub-parts: Part A, a single ascending dose study (SAD) in normal human volunteers (NHVs), Part B, a multiple ascending dose study (MAD) in…
- Conditions
- Bullous Pemphigoid (BP), Cold Agglutinin Disease (CAD), Warm Autoimmune Hemolytic Anemia (WAIHA), End-stage Renal Disease (ESRD)
- Trial name
- BIVV009-01 (NCT02502903)
- Testing
- BIV009
- Where
- Austria
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Bioverativ, a Sanofi company
Non-bullous Impetigo
A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo
The purpose of this study is to determine the efficacy of the topical antibiotic LTX-109 in terms of clinical and microbiological response in treatment of impetigo.
- Trial name
- NCT01803035
- Testing
- LTX-109 1 %, LTX-109 2 %
- Where
- 2 sites in Dominican Republic
- Volunteers
- 210 people
- Sponsor
- Lytix Biopharma AS
Autoimmune Bullous Dermatosis
Coagulopathy of Immunodermatologic Diseases
This study will examine the coagulation and fibrinolysis profiles of those with autoimmune skin diseases. Blood samples will be collected from participants with active/poorly controlled immune-mediated skin diseases and…
- Trial name
- NCT06037187
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Bullous Pemphigoid
Deciphering IL-17-dependant Inflammatory Response in Bullous Pemphigoid
Bullous pemphigoid (BP) is the most frequent autoimmune skin disease and mainly affects elderly individuals. BP classically manifests with tense blisters over urticarial plaques on the trunk and extremities accompanied by intense…
- Trial name
- BP-IL17RB (NCT06479018)
- Testing
- Blood sampling, Liquid bubble sampling, Cutaneous biopsy
- Where
- France
- Volunteers
- 140 people
- Sponsor
- CHU de Reims
Stevens-Johnson Syndrome, Lyell Syndrome
Drug Reactions Sampling (COLLECTIONTOXIDERMIES)
Intro: Dermatology department of Henri Mondor Hospital (Creteil, France), is a reference center for toxic bullous diseases and severe cutaneous drug reactions (Stevens-Johnson syndrome (SJS), Lyell syndrome (toxic epidermal…
- Conditions
- Stevens-Johnson Syndrome, Lyell Syndrome, Drug Reactions, AGEP
- Trial name
- NCT03659227
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris